Clinical Trial Update: RANKL Inhibition and Breast Tissue Biomarkers [EARLY_Phase 1]

View source ↗

Summary

Early-phase trial update on RANKL inhibition and breast tissue biomarkers in the context of breast cancer prevention and mammographic density. The study examine…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Denosumab (denosumab)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Breast Cancer Prevention, Mammographic Density | EARLY_Phase 1 | Status: COMPLETED